OP White Papers - random
-
Switching To Direct-To-Patient Rapidly In The EU
10/4/2022
Explore the logistical risk management factors to consider when deciding to switch to direct-to-patient shipments in the EU.
-
Efficient, Large-Scale Transfection Of T-Cells Using Flowfect® Technology
2/26/2023
The objective of this study was to test transfection of T-cells with GFP mRNA for evaluation of cell viability, transfection efficiency, and post-transfection growth using Kytopen’s Flowfect® technology.
-
Integrated First-In-Human Services To Streamline End-To-End Development And Manufacturing
6/1/2022
Lonza’s SimpliFiH®️ Solutions offering is designed to simplify and accelerate the development pathway, even for APIs with challenging properties, such as low aqueous solubility and poor bioavailability.
-
β-Glucan As A Process-Related Impurity In Biopharmaceuticals
5/17/2022
In this white paper, we dig deeper into the sources of β-glucan, its influence on manufacturing and patient safety, and ways to detect and control its amounts in the finished drug product.
-
Reducing ADC Timelines With Integrated Development And Manufacturing Services
4/8/2024
ADCs have proven to be highly effective in cancer treatment, but their manufacturing poses challenges. Learn how a CDMO partner can help bring these treatments to patients safely and efficiently.
-
Validated HPLC-UV Method For Quantification Of Paxalisib
1/18/2023
Examine research into the development and validation of a HPLC method for the quantitation of paxalisib in mouse plasma and its potential use for routine therapeutic drug monitoring.
-
Increasing Bioavailability With Amorphous Solid Dosage Formulations
11/10/2023
Discover the challenges associated with pH-dependent solubility for oral tyrosine kinase inhibitor drugs and how leveraging ASD formulation can help create more effective, patient-friendly drug products.
-
The Business Case For Pharmaceutical Continuous Manufacturing
6/2/2023
Examine a step-by-step approach outlining the business cases that support adopting continuous manufacturing, with considerations for innovators, generics manufacturers, CDMOs, and OTC suppliers.
-
Placing Drug Strategies On A Solid Foundation For Success
4/21/2022
Explore how certain drivers are impacting traditional drug development strategies and relationships with outsourced drug development and manufacturing partners.
-
Cell Line Development: The Linchpin In Successful Biotherapeutic Development
1/4/2024
Review key factors for building a reliable CLD strategy and learn how the right CDMO can help you achieve the high quality, high yield, and speed needed to successfully bring a biologic to market.